ATRA vs. TIL, DTIL, ELUT, TSBX, CGTX, IKNA, JATT, GNTA, ENTX, and ATHA
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Instil Bio (TIL), Precision BioSciences (DTIL), Elutia (ELUT), Turnstone Biologics (TSBX), Cognition Therapeutics (CGTX), Ikena Oncology (IKNA), JATT Acquisition (JATT), Genenta Science (GNTA), Entera Bio (ENTX), and Athira Pharma (ATHA). These companies are all part of the "biological products, except diagnostic" industry.
Atara Biotherapeutics (NASDAQ:ATRA) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.
Instil Bio has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -671.70%. Instil Bio's return on equity of -51.27% beat Atara Biotherapeutics' return on equity.
Atara Biotherapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
Atara Biotherapeutics presently has a consensus target price of $28.00, indicating a potential upside of 4,538.83%. Instil Bio has a consensus target price of $25.00, indicating a potential upside of 111.86%. Given Atara Biotherapeutics' higher probable upside, research analysts plainly believe Atara Biotherapeutics is more favorable than Instil Bio.
Atara Biotherapeutics received 335 more outperform votes than Instil Bio when rated by MarketBeat users. Likewise, 67.67% of users gave Atara Biotherapeutics an outperform vote while only 52.51% of users gave Instil Bio an outperform vote.
70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 4.5% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 54.7% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Instil Bio has lower revenue, but higher earnings than Atara Biotherapeutics. Instil Bio is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Instil Bio had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for Instil Bio and 6 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.95 beat Instil Bio's score of -0.24 indicating that Atara Biotherapeutics is being referred to more favorably in the media.
Summary
Instil Bio beats Atara Biotherapeutics on 9 of the 17 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atara Biotherapeutics Competitors List
Related Companies and Tools
